Alkeus Pharmaceuticals
- Biotech or pharma, therapeutic R&D
Alkeus is a late-stage, private biopharmaceutical company harnessing breakthrough science to transform care for retinal diseases. Alkeus is developing gildeuretinol for the treatment of Stargardt disease and plans to file an NDA in 2025. Gildeuretinol is also in development for geographic atrophy.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}